Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 2 1

Status

Completed 12Not yet recruiting 2Withdrawn 1Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 305Carcinoma, Non-Small-Cell Lung 287Colorectal Neoplasms 159Prostatic Neoplasms 158Carcinoma, Hepatocellular 144Neoplasms 137Leukemia, Myeloid, Acute 131Lung Neoplasms 117Squamous Cell Carcinoma of Head and Neck 108Multiple Myeloma 104Triple Negative Breast Neoplasms 102Recurrence 101Pancreatic Neoplasms 96Stomach Neoplasms 94Ovarian Neoplasms 89Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Esophageal Neoplasms 68Uterine Cervical Neoplasms 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Melanoma 67Brain Neoplasms 67Rectal Neoplasms 64Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 58Myelodysplastic Syndromes 55Lymphoma 55Esophageal Squamous Cell Carcinoma 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Condylomata Acuminata × Clear all
NCT06756269 2025-12-17

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

Shanghai Bovax Biotechnology Co., Ltd.

Phase 2 Recruiting
330 enrolled

Condylomata Acuminata, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡